Parameter | Probability of event/28Â days, % (SE) | [Source] | |||||
---|---|---|---|---|---|---|---|
Sputum culture conversion on BR, 0–8 weeks (log-normal) | |||||||
 Scale parameter | 4.99 (0.21) | Placebo-controlled phase II clinical trial C208 [12] | |||||
 Shape parameter | 0.73 (0.11) | Placebo-controlled phase II clinical trial C208 [12] | |||||
Sputum culture conversion on BR, 8–24 weeks (log-normal) | |||||||
 Scale parameter | 5.68 (0.40) | Placebo-controlled phase II clinical trial C208 [12] | |||||
 Shape parameter | 1.90 (0.27) | Placebo-controlled phase II clinical trial C208 [12] | |||||
Sputum culture conversion on BR, ≥24 weeks (log-normal) | |||||||
 Scale parameter | 8.28 (1.09) | Placebo-controlled phase II clinical trial C208 [12] | |||||
 Shape parameter | 2.70 (0.82) | Placebo-controlled phase II clinical trial C208 [12] | |||||
Subsequent MDR-TB | |||||||
 Hazard ratio of subsequent MDR-TB (vs. initial MDR-TB) | 0.54 (0.17) | Open-label, phase II clinical trial C209 [13] | |||||
Other events | |||||||
 Probability of reversion | 1 (0.30) | Placebo-controlled phase II clinical trial C208 [12] | |||||
 Probability of death | MDR-TB, no cure | 2.21 | |||||
MDR-TB, cure | 0.32 | ||||||
XDR-TB, no cure | 2.69 | ||||||
XDR-TB, cure | 0.39 | ||||||
Treatment effect | |||||||
 Hazard ratio of bedaquiline (sputum culture conversion) | 2.44 (0.57) | Placebo-controlled phase II clinical trial C208 [12] | |||||
 Hazard ratio of bedaquiline (relapse) | 0.32 (0.25) | Placebo-controlled phase II clinical trial C208 [12] | |||||
 Hazard ratio (XDR-TB) | 0.40 (0.11) | Open-label, phase II clinical trial C209 [13] | |||||
 | Estoniaa | Russiab | South Africaa | Perua | Chinaa | Philippinesa | Indiaa |
Probability of loss to follow-up, % (SE) | 1.4 (4.1) | 1.5 (0.3) | 1.4 (0.4) | 1.5 (0.8) | 0.6 (0.7) | 3.4 (1.6) | 1.2 (0.6) |